| abstract |
The present invention relates to binding molecules comprising at least three binding specificities, wherein (a) the first specificity is against a hepatitis B virus (HBV) surface antigen selected from the group consisting of HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen (b) (i) the second and third specificities are for CD3 and CD28, respectively; or (ii) the second and third specificities are selected from the group consisting of specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D (c) each binding specificity is provided by one or more binding sites, each binding site is independently provided by: (i) a set of six complementarity determining regions (CDRs), wherein the six The set of CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein the first set and the second set are each contained in an immunoglobulin domain; or (ii) three A set of three CDRs, wherein the set of three CDRs is contained in an immunoglobulin domain. |